NASDAQ:ZIOP - Ziopharm Oncology Stock Price, Price Target & More

Get Started

$4.45 -0.02 (-0.45 %)

(As of 05/21/2018 10:32 AM ET)

Previous Close$4.47

Today's Range$4.44 - $4.54

52-Week Range$3.33 - $7.55

Volume88,800 shs

Average Volume1.45 million shs

Market Capitalization$637.65 million

P/E Ratio-8.40

Dividend YieldN/A

Beta1.74

About Ziopharm Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ZIOP

CUSIP98973P10

Webwww.ziopharm.com

Phone617-259-1970

Debt

Debt-to-Equity RatioN/A

Current Ratio7.17

Quick Ratio7.17

Price-To-Earnings

Trailing P/E Ratio-8.40

Forward P/E Ratio-8.56

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million

Price / Sales99.34

Cash FlowN/A

Price / CashN/A

Book Value($0.68) per share

Price / Book-6.54

Profitability

EPS (Most Recent Fiscal Year)($0.53)

Net Income$-54,320,000.00

Net Margins-1,212.13%

Return on EquityN/A

Return on Assets-54.86%

Miscellaneous

Employees46

Outstanding Shares142,650,000

Ziopharm Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is Ziopharm Oncology's stock symbol?

Ziopharm Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were Ziopharm Oncology's earnings last quarter?

Ziopharm Oncology Inc (NASDAQ:ZIOP) issued its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $0.15 million for the quarter, compared to analyst estimates of $1.55 million. View Ziopharm Oncology's Earnings History.

When is Ziopharm Oncology's next earnings date?

Ziopharm Oncology is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Ziopharm Oncology.

What price target have analysts set for ZIOP?

2 analysts have issued 12 month target prices for Ziopharm Oncology's shares. Their forecasts range from $5.50 to $5.50. On average, they expect Ziopharm Oncology's share price to reach $5.50 in the next year. View Analyst Ratings for Ziopharm Oncology.

What are Wall Street analysts saying about Ziopharm Oncology stock?

Here are some recent quotes from research analysts about Ziopharm Oncology stock:

1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)

Are investors shorting Ziopharm Oncology?

Ziopharm Oncology saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 35,652,139 shares, an increase of 0.1% from the April 13th total of 35,620,362 shares. Based on an average daily volume of 751,219 shares, the short-interest ratio is presently 47.5 days. Currently, 28.0% of the shares of the company are sold short.

Who are some of Ziopharm Oncology's key competitors?

Some companies that are related to Ziopharm Oncology include Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Puma Biotechnology (PBYI) and Enanta Pharmaceuticals (ENTA).

Who are Ziopharm Oncology's key executives?

Ziopharm Oncology's management team includes the folowing people:

Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.

Has Ziopharm Oncology been receiving favorable news coverage?

News coverage about ZIOP stock has trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ziopharm Oncology earned a media sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Ziopharm Oncology's major shareholders?

Ziopharm Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.92%), UBS Group AG (0.61%), Schwab Charles Investment Management Inc. (0.47%), Wells Fargo & Company MN (0.18%), Russell Investments Group Ltd. (0.16%) and Mackay Shields LLC (0.06%). Company insiders that own Ziopharm Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for Ziopharm Oncology.

Which major investors are selling Ziopharm Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, BlackRock Inc., MetLife Investment Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Ziopharm Oncology.

Which major investors are buying Ziopharm Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., UBS Group AG, Mackay Shields LLC, Private Advisor Group LLC, Wealthcare Advisory Partners LLC, Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. Company insiders that have bought Ziopharm Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for Ziopharm Oncology.

How do I buy shares of Ziopharm Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ziopharm Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $4.45.

How big of a company is Ziopharm Oncology?

Ziopharm Oncology has a market capitalization of $637.65 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Ziopharm Oncology employs 46 workers across the globe.

How can I contact Ziopharm Oncology?

Ziopharm Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

MarketBeat Community Rating for Ziopharm Oncology (ZIOP)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		210 (Vote Outperform)
Underperform Votes:		251 (Vote Underperform)
Total Votes:		461

MarketBeat's community ratings are surveys of what our community members think about Ziopharm Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Ziopharm Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Ziopharm Oncology in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 23.60%. The high price target for ZIOP is $5.50 and the low price target for ZIOP is $5.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.67	2.67
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.50	$10.00	$16.50	$16.25
Price Target Upside:	23.60% upside	147.52% upside	271.62% upside	247.97% upside

Ziopharm Oncology (NASDAQ:ZIOP) Consensus Price Target History

Price Target History for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/14/2018	HC Wainwright	Reiterated Rating	Buy	$5.50	Low
12/11/2017	Raymond James	Reiterated Rating	Hold		High
2/28/2017	Griffin Securities	Reiterated Rating	Buy	$23.00	N/A
1/12/2017	JPMorgan Chase	Reiterated Rating	Hold		N/A
8/10/2016	Wells Fargo	Upgrade	Underperform ➝ Market Perform		N/A
7/18/2016	Mizuho	Reiterated Rating	Neutral	$7.00 ➝ $5.00	N/A

(Data available from 5/21/2016 forward)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings History and Estimates Chart

Earnings by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q3 2018	1	($0.14)	($0.14)	($0.14)
Q4 2018	1	($0.14)	($0.14)	($0.14)

Ziopharm Oncology (NASDAQ ZIOP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/30/2018
5/10/2018	Q1 2018	($0.13)	($0.15)	$1.55 million	$0.15 million	View	N/A
3/1/2018	Q4 2017	($0.13)	($0.13)	$1.59 million	$1.60 million	View	Listen
11/6/2017	Q3 2017	($0.13)	($0.13)	$1.66 million	$1.60 million	View	N/A
7/31/2017	Q2 2017	($0.13)	($0.13)	$1.66 million	$1.60 million	View	N/A
5/1/2017	Q1 2017	($0.12)	($0.15)	$1.71 million	$1.60 million	View	Listen
2/16/2017	Q4 2016	($0.11)	($0.11)	$1.62 million	$1.60 million	View	N/A
11/9/2016	Q3 2016	($0.11)	($0.11)	$1.45 million	$1.60 million	View	N/A
8/9/2016	Q216	($0.11)	($1.01)	$1.52 million	$1.70 million	View	N/A
5/10/2016	Q1	($0.08)	($0.09)	$1.89 million	$1.97 million	View	N/A
2/24/2016	Q4	($0.07)	($0.07)	$1.82 million	$1.92 million	View	N/A
11/2/2015	Q315	($0.13)	($0.14)	$1.19 million	$1.90 million	View	N/A
8/10/2015	Q2	($0.22)	($0.11)	$57.70 million	$0.27 million	View	N/A
5/7/2015		($0.13)	($0.10)	$0.20 million	$0.30 million	View	N/A
2/26/2015	Q414	($0.14)	($0.09)	$420.00 million	$0.34 million	View	N/A
10/30/2014	Q314	($0.12)	($0.06)	$0.20 million	$0.63 million	View	N/A
8/7/2014	Q214	($0.17)	($0.06)	$7.50 million	$0.20 million	View	N/A
5/8/2014	Q114	($0.10)	($0.10)	$0.20 million	$0.20 million	View	N/A
3/3/2014	Q413	($0.15)	($0.09)	$0.20 million	$0.20 million	View	N/A
10/22/2013	Q313	($0.17)	($0.20)		$0.20 million	View	N/A
8/8/2013	Q2 2013	($0.24)	($0.22)	$0.20 million	$0.20 million	View	N/A
5/7/2013	Q1 2013	($0.28)	($0.28)	$0.20 million	$0.20 million	View	N/A
3/18/2013	Q4 2012	($0.29)	($0.48)	$0.17 million	$0.20 million	View	N/A
11/8/2012	Q312	($0.28)	($0.28)	$0.20 million	$0.20 million	View	N/A
8/2/2012		($0.23)	($0.29)			View	N/A
5/3/2012		($0.22)	($0.25)			View	N/A
2/29/2012		($0.23)	($0.24)			View	N/A
11/3/2011		($0.28)	($0.01)			View	N/A
8/1/2011		($0.23)	($0.16)			View	N/A
5/5/2011	Q1 2011	($0.17)	($0.18)			View	N/A
3/1/2011	Q4 2010	($0.25)	($0.25)			View	N/A
11/4/2010	Q3 2010	($0.17)	($0.18)			View	N/A
7/30/2010	Q2 2010	($0.13)	$0.19			View	N/A
4/30/2010	Q1 2010	($0.10)	($0.11)			View	N/A
3/18/2010	Q4 2009	($0.12)	$0.03			View	N/A
11/11/2009	Q3 2009		($0.13)			View	N/A
8/14/2009	Q2 2009		($0.10)			View	N/A
5/15/2009	Q1 2009		($0.16)			View	N/A
3/24/2009	Q4 2008	($0.19)	($0.21)			View	N/A
10/30/2008	Q3 2008	($0.23)	($0.26)			View	N/A
7/31/2008	Q2 2008	($0.36)	($0.31)			View	N/A
5/12/2008	Q1 2008	($0.35)	($0.41)			View	N/A
2/22/2008	Q4 2007	($0.39)	($0.36)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Ziopharm Oncology (NASDAQ:ZIOP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 39.94%

Insider Trading History for Ziopharm Oncology (NASDAQ:ZIOP)

Institutional Ownership by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2017	David M Md Mauney	EVP	Buy	4,270	$4.68	$19,983.60	58,662
11/8/2017	Laurence James Neil Cooper	CEO	Buy	6,440	$4.68	$30,139.20	1,083,731
6/4/2015	Murray Brennan	Director	Sell	40,000	$9.70	$388,000.00
2/9/2015	Randal J Kirk	Director	Buy	1,440,000	$8.75	$12,600,000.00
10/29/2013	Randal J Kirk	Director	Buy	2,857,143	$3.50	$10,000,000.50

(Data available from 1/1/2013 forward)

Ziopharm Oncology (NASDAQ ZIOP) News Headlines

Source:

Date	Headline
	Ziopharm Oncology (ZIOP) Downgraded by BidaskClub to "Sell" www.americanbankingnews.com - May 19 at 10:57 AM
	Equities Analysts Offer Predictions for Ziopharm Oncology Inc's Q3 2018 Earnings (ZIOP) www.americanbankingnews.com - May 17 at 7:00 AM
	Head-To-Head Comparison: Ziopharm Oncology (ZIOP) vs. Horizon Pharma (HZNP) www.americanbankingnews.com - May 17 at 5:19 AM
	Ziopharm Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - May 16 at 4:29 PM
	New Research: Key Drivers of Growth for root9B Holdings Inc., Comfort Systems ... www.nasdaq.com - May 16 at 10:23 AM
	Brokers Issue Forecasts for Ziopharm Oncology Inc's FY2022 Earnings (ZIOP) www.americanbankingnews.com - May 16 at 8:20 AM
	Ziopharm Oncology (ZIOP) Receives "Buy" Rating from HC Wainwright www.americanbankingnews.com - May 14 at 11:40 AM
	Ziopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think seekingalpha.com - May 14 at 11:06 AM
	Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc. finance.yahoo.com - May 12 at 10:16 AM
	BRIEF-Ziopharm Oncology Reports Q1 Loss Per Share $0.15 www.reuters.com - May 11 at 4:25 PM
	Here's What's Causing Intrexon to Tumble 20% Today finance.yahoo.com - May 11 at 4:25 PM
	Ziopharm Q1 cash balance $51M; delays pivotal study of Ad-RTS-hIL-12 in glioblastoma; shares down 3% after hours seekingalpha.com - May 11 at 10:50 AM
	ZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 11 at 10:50 AM
	Edited Transcript of ZIOP earnings conference call or presentation 10-May-18 8:30pm GMT finance.yahoo.com - May 11 at 10:50 AM
	Ziopharm: 1Q Earnings Snapshot finance.yahoo.com - May 11 at 10:50 AM
	Ziopharm Oncology (ZIOP) Releases Earnings Results, Misses Expectations By $0.02 EPS www.americanbankingnews.com - May 10 at 6:28 PM
	Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update finance.yahoo.com - May 10 at 4:17 PM
	Ziopharm Oncology (ZIOP) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - May 9 at 11:45 AM
	Ziopharm Oncology (ZIOP) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - May 9 at 8:52 AM
	Ziopharm Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.55 Million www.americanbankingnews.com - May 6 at 2:06 AM
	Zacks Investment Research Downgrades Ziopharm Oncology (ZIOP) to Strong Sell www.americanbankingnews.com - May 5 at 8:09 PM
	Ziopharm Oncology Inc (ZIOP) Expected to Post Earnings of -$0.13 Per Share www.americanbankingnews.com - May 4 at 10:03 PM
	Ziopharm Oncology (ZIOP) Upgraded to Sell at ValuEngine www.americanbankingnews.com - May 2 at 1:15 PM
	Ziopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - April 19 at 10:42 AM
	Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million www.americanbankingnews.com - April 19 at 2:28 AM
	Ziopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 17 at 10:21 PM
	-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter www.americanbankingnews.com - April 17 at 7:27 PM
	Ziopharm Oncology (ZIOP) Given a $10.00 Price Target at HC Wainwright www.americanbankingnews.com - April 14 at 3:36 PM
	Ziopharm Oncology (ZIOP) Raised to Hold at BidaskClub www.americanbankingnews.com - April 13 at 9:39 AM
	Ziopharm Oncology (ZIOP) Downgraded by ValuEngine to Sell www.americanbankingnews.com - April 10 at 4:28 PM
	Ziopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 5 at 12:30 AM
	Global Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene Corporation www.marketwatch.com - April 4 at 5:22 PM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 Million www.americanbankingnews.com - April 2 at 2:12 AM
	Edited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMT finance.yahoo.com - April 1 at 9:51 AM
	Zacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per Share www.americanbankingnews.com - March 31 at 7:12 PM
	ZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - March 30 at 5:08 PM
	Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ) www.americanbankingnews.com - March 23 at 7:08 PM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 Million www.americanbankingnews.com - March 16 at 3:44 AM
	Zacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to Sell www.americanbankingnews.com - March 15 at 12:50 PM
	-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter www.americanbankingnews.com - March 14 at 5:24 PM
	Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7% www.americanbankingnews.com - March 12 at 2:14 AM
	ZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 9 at 9:02 PM
	ZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call Slides seekingalpha.com - March 5 at 4:25 PM
	ZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC Wainwright www.americanbankingnews.com - March 5 at 11:48 AM
	Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat finance.yahoo.com - March 2 at 4:13 PM
	ZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 1 at 11:30 PM
	ZIOPHARM Oncology (ZIOP) Announces Earnings Results www.americanbankingnews.com - March 1 at 9:12 PM
	Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update finance.yahoo.com - March 1 at 4:19 PM
	ZIOPHARM Oncology Inc. (ZIOP) Sees Large Growth in Short Interest www.americanbankingnews.com - March 1 at 2:40 AM
	ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.59 Million www.americanbankingnews.com - February 27 at 4:16 AM

Ziopharm Oncology (NASDAQ:ZIOP) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Ziopharm Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement

Ziopharm Oncology (NASDAQ ZIOP) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff